当前位置: X-MOL 学术Nat. Rev. Drug. Disc. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Yong-Jun Liu
Nature Reviews Drug Discovery ( IF 120.1 ) Pub Date : 2017-06-29 , DOI: 10.1038/nrd.2017.127


Yong-Jun Liu is a drug discovery veteran with a career that has spanned both academia and industry. Since 2002 he has overseen drug discovery programmes at the University of Texas MD Anderson Cancer Center, Baylor Research Institute and AstraZeneca's biologics company MedImmune. He added another large pharma firm to this roster in 2016, when he joined Sanofi as head of research. Sanofi's president of global R&D Elias Zerhouni prioritized the development-stage pipeline during the first years of his tenure at the company, but brought Liu on board last year to refocus on the internal early-stage drug discovery efforts. Liu spoke with Asher Mullard about his first year at Sanofi and the company's emphasis on multi-targeted therapeutics.

中文翻译:

刘永军

刘勇军(Yong-Jun Liu)是一名从事药物发现的资深人士,其职业生涯横跨学术界和工业界。自2002年以来,他负责德克萨斯大学MD安德森癌症中心,贝勒研究所和阿斯利康生物制药公司MedImmune的药物发现计划。当他加入赛诺菲担任研究主管时,他于2016年将另一家大型制药公司加入了这一名单。赛诺菲全球研发部总裁Elias Zerhouni在公司任职的头几年就优先考虑开发阶段的管道,但去年刘先生加入了公司,重新专注于内部早期药物开发工作。Liu与Asher Mullard谈了他在赛诺菲的第一年,以及该公司对多目标疗法的重视。
更新日期:2017-06-29
down
wechat
bug